Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: A nation-wide analysis in Japan

Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R‐CHOP regimen: a nationwide real‐world study in Japan

“…Our study highlighted a requirement for chemotherapeutic dose reduction in very elderly patients to prevent FN. The efficacy of pegfilgrastim was limited in the very elderly patients in the present study, consistent with our previous study 7 . In the very elderly patients, only reduction in chemotherapeutic dose was significantly associated with lower occurrence of FN.…”

“…The efficacy of pegfilgrastim was limited in the very elderly patients in the present study, consistent with our previous study. 7 In the very elderly patients, only reduction in chemotherapeutic dose was significantly associated with lower occurrence of FN. Although reduction in chemotherapeutic dose was reported to be a risk factor for impaired treatment effect, 15,16 the risk may be minimized in very elderly patients.…”

“…3 The CIS-fatigue (subscale; 8 items) and the shortened CIS (4 items) can be used independently and have a cut-off for severe fatigue, which may identify patients who could benefit from an intervention. [7][8][9] Although diseasespecific quality-of-life tools may be more appropriate to evaluate the general effect of ITP treatment, the CIS respects patients' own emphasis on fatigue and is better suited to evaluate fatigue-targeted interventions.…”

“…The results showed that appropriate use of G‐CSF reduced FN susceptibility and provided health‐economic benefits. We further analysed the prophylactic effect of G‐CSF according to age groups and found that the efficacy may be limited in very elderly patients aged ≥80 years 7 …”

“…We further analysed the prophylactic effect of G-CSF according to age groups and found that the efficacy may be limited in very elderly patients aged ≥80 years. 7 These results raised the possibility that very elderly patients had unique sensitivity to FN and suggested that different management strategies may be required for these patients. However, no comprehensive analyses have evaluated the FN risk in very elderly patients.…”